Avacta Group Plc (RTQ1.F)
Frankfurt · EUR · Healthcare · Biotechnology
€0.73 (-0.68%) as of
Key statistics
- Market cap
- 319.47M
- EPS (TTM)
- -0.1000
- Dividend yield
- 0.00%
- 52-week range
- 0.5550 – 1.0400
- Beta
- -0.16
- Revenue (TTM)
- 113k
- Profit margin
- 0.00%
- Volume
- 3.45k
About Avacta Group Plc
Avacta Group Plc, together with its subsidiaries, engages in the development of cancer therapies in the United Kingdom, South Korea, and internationally. The company's lead product candidate is AVA6000, a peptide drug conjugate form of doxorubicin, which is an approved cancer drug with known severe toxicities. It also develops AVA6103, a peptide drug conjugate technology designed to deliver exatecan, a potent topoisomerase I inhibitor directly to tumors while limiting the exposure of the released exatecan in normal tissues; and AVA7100 that drives localization to fibroblast activation protein expressing tumors. The company was incorporated in 2003 and is headquartered in London, the United Kingdom.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- London, United Kingdom
- Employees
- 81
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.